<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">ACS Infect Dis</journal-id><journal-id journal-id-type="publisher-id">id</journal-id><journal-id journal-id-type="coden">aidcbc</journal-id><journal-title-group><journal-title>ACS Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2373-8227</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7437450</article-id><article-id pub-id-type="doi">10.1021/acsinfecdis.0c00522</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Anti-SARS-CoV-2 Potential of Artemisinins In
Vitro</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Cao</surname><given-names>Ruiyuan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-1" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Hu</surname><given-names>Hengrui</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="notes-1" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Li</surname><given-names>Yufeng</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="notes-1" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Wang</surname><given-names>Xi</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Xu</surname><given-names>Mingyue</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Liu</surname><given-names>Jia</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Zhang</surname><given-names>Huanyu</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Yan</surname><given-names>Yunzheng</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Zhao</surname><given-names>Lei</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Li</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Zhang</surname><given-names>Tianhong</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Xiao</surname><given-names>Dian</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Guo</surname><given-names>Xiaojia</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath14"><name><surname>Li</surname><given-names>Yuexiang</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath15"><name><surname>Yang</surname><given-names>Jingjing</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath16"><name><surname>Hu</surname><given-names>Zhihong</given-names></name><xref rid="cor3" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath17"><name><surname>Wang</surname><given-names>Manli</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath18"><name><surname>Zhong</surname><given-names>Wu</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>National Engineering Research Center
for the Emergency Drug, <institution>Beijing Institute of Pharmacology
and Toxicology</institution>, Beijing 100850,
<country>China</country></aff><aff id="aff2"><label>&#x02021;</label>State Key Laboratory of Virology,
Wuhan Institute of Virology, Center for Biosafety Mega-Science,
<institution>Chinese Academy of Sciences</institution>, Wuhan
430071, <country>P. R. China</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>University of the Chinese
Academy of Sciences</institution>, Beijing 100049, <country>P.
R. China</country></aff><aff id="aff4"><label>&#x02225;</label><institution>Guoke Excellence
(Beijing) Medicine Technology Research Co., Ltd.</institution>,
Beijing 100176, <country>P. R. China</country></aff></contrib-group><author-notes><corresp id="cor3"><label>*</label>Tel/Fax: <phone>86-27-87197180</phone>.
E-mail: <email>huzh@wh.iov.cn</email>.</corresp><corresp id="cor2"><label>*</label>Tel/Fax: <phone>86-27-87197340</phone>.
E-mail: <email>wangml@wh.iov.cn</email>.</corresp><corresp id="cor1"><label>*</label>Tel: <phone>86-10-66932624</phone>.
E-mail: <email>zhongwu@bmi.ac.cn</email>.</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>07</month><year>2020</year></pub-date><elocation-id>acsinfecdis.0c00522</elocation-id><history><date date-type="received"><day>21</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 American Chemical Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for
unrestricted RESEARCH re-use and analyses in any form or by any
means with acknowledgement of the original source. These
permissions are granted for the duration of the World Health
Organization (WHO) declaration of COVID-19 as a global
pandemic.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_0006" id="ab-tgr1"/></p><p>The discovery of novel drug candidates with anti-severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) potential is
critical for the control of the global COVID-19 pandemic.
Artemisinin, an old antimalarial drug derived from Chinese
herbs, has saved millions of lives. Artemisinins are a cluster
of artemisinin-related drugs developed for the treatment of
malaria and have been reported to have multiple pharmacological
activities, including anticancer, antiviral, and immune
modulation. Considering the reported broad-spectrum antiviral
potential of artemisinins, researchers are interested in whether
they could be used to combat COVID-19. We systematically
evaluated the anti-SARS-CoV-2 activities of nine
artemisinin-related compounds <italic>in vitro</italic> and
carried out a time-of-drug-addition assay to explore their
antiviral mode of action. Finally, a pharmacokinetic prediction
model was established to predict the therapeutic potential of
selected compounds against COVID-19. Arteannuin B showed the
highest anti-SARS-CoV-2 potential with an EC<sub>50</sub> of
10.28 &#x000b1; 1.12 &#x003bc;M. Artesunate and dihydroartemisinin
showed similar EC<sub>50</sub> values of 12.98 &#x000b1; 5.30
&#x003bc;M and 13.31 &#x000b1; 1.24 &#x003bc;M, respectively, which
could be clinically achieved in plasma after intravenous
administration. Interestingly, although an EC<sub>50</sub> of
23.17 &#x000b1; 3.22 &#x003bc;M was not prominent among the tested
compounds, lumefantrine showed therapeutic promise due to high
plasma and lung drug concentrations after multiple dosing.
Further mode of action analysis revealed that arteannuin B and
lumefantrine acted at the post-entry step of SARS-CoV-2
infection. This research highlights the anti-SARS-CoV-2
potential of artemisinins and provides leading candidates for
anti-SARS-CoV-2 drug research and development.</p></abstract><kwd-group><kwd>artemisinin</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>antiviral drug</kwd><kwd>drug repurposing</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>id0c00522</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>id0c00522</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">The COVID-19 pandemic caused by severe acute respiratory coronavirus 2
(SARS-CoV-2) has taken a heavy toll on public health and the global economy.
As of July 18, 2020, 13.9 million confirmed cases including 593&#x0202f;087
deaths have been reported worldwide since the pathogen was first identified
in January 2020.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> Unfortunately, there are currently no specific and
effective antiviral drugs available to treat a large number of infected
patients. Chloroquine, hydroxychloroquine, remdesivir, and
lopinavir/ritonavir were highlighted as repurposed drugs to treat COVID-19.
However, according to the COVID-19 Treatment Guidelines released by the NIH
in April 21, 2020, there are insufficient clinical data to recommend either
for or against the use of chloroquine, hydroxychloroquine, and remdesivir
for the treatment of COVID-19, and the use of lopinavir/ritonavir or other
HIV protease inhibitors was no longer recommended.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup>
Although a series of Food and Drug Administration (FDA)-approved drugs that
are capable of inhibiting SARS-CoV-2 <italic>in vitro</italic> were
reported, the discovery of more drug candidates with anti-SARS-CoV-2
potential is urgently needed to fuel antiviral drug research for
COVID-19.</p><p>Previously, we reported that chloroquine, a decades-old antimalarial drug with
immune-modulation activities, and its derivative hydroxychloroquine could
efficiently inhibit SARS-CoV-2 <italic>in
vitro</italic>.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup> This raises an interesting question
of whether other antimalarial drugs also have anti-SARS-CoV-2
potential.<sup><xref ref-type="bibr" rid="ref6">6</xref>&#x02212;<xref ref-type="bibr" rid="ref8">8</xref></sup> Artemisinins comprise another series of well-known
antimalarials with immune-modulatory activities. Among the reported
artemisinins, artemisinin, dihydroartemisinin,
artemether&#x02013;lumefantrine, artesunate, arteether, and artemisone are
approved drugs derived from artemisinin.<sup><xref ref-type="bibr" rid="ref9">9</xref>&#x02212;<xref ref-type="bibr" rid="ref11">11</xref></sup> Arteannuin B and artemisinic acid
are artemisinin derivatives reported to have therapeutic efficacy against
malaria <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> Previous studies have reported the
broad-spectrum antiviral potential of artemisinins. For example, artesunate
effectively inhibits a wide range of DNA and RNA viruses, including human
cytomegalovirus (HCMV), human herpes simplex virus (HSV), hepatitis B virus
(HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and
polyomavirus BK.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> Clinical trials focusing on the
antiviral efficacy of artesunate suggested that it shows promise for the
treatment of patients with HCMV and HSV-2 infection.<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref16">16</xref></sup>
Dihydroartemisinin also showed inhibitory effects on viruses such as HCMV
and Zika virus.<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup> In addition, artemisone was proven to be a potent
inhibitor of HCMV and had synergistic antiviral activity in combination with
other approved and experimental anti-HCMV agents.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> Considering
the broad-spectrum antiviral effects of artemisinins, it is necessary to
systematically explore the anti-SARS-CoV-2 potential of artemisinins, which
consists of multiple FDA-approved drugs and drug candidates at the late
stage of pharmacological development, and predict their therapeutic efficacy
based on a physiologically based pharmacokinetic (PBPK) modeling.</p><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Artemisinins Inhibit SARS-CoV-2 In Vitro</title><p>In this study, nine artemisinins (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>) were chosen to test their
anti-SARS-CoV-2 potential using African green monkey kidney Vero E6
cells. Cytotoxicity assays were carried out before the antiviral assay
to determine the cytotoxicity of the selected compounds, and viral RNA
copies in the supernatants were determined by quantitative real-time
PCR (qRT-PCR) to determine the antiviral effects of the compounds. The
results showed that the half-cytotoxic concentrations
(CC<sub>50</sub>) of arteether, artemether, artemisic acid,
artemisinin, and artemisone were greater than 200 &#x003bc;M. However,
the half-maximal effective concentrations (EC<sub>50</sub>) were 31.86
&#x000b1; 4.72 &#x003bc;M, 73.80 &#x000b1; 26.91 &#x003bc;M, &#x0003e;100 &#x003bc;M,
64.45 &#x000b1; 2.58 &#x003bc;M, and 49.64 &#x000b1; 1.85 &#x003bc;M,
respectively for these compounds, indicating suboptimal selective
indexes (SIs) (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The
EC<sub>50</sub> of dihydroartemisinin was 13.31 &#x000b1; 1.24
&#x003bc;M and the SI was 2.38 &#x000b1; 0.22. Notably, artesunate, which
was reported to have broad-spectrum antiviral potential against
multiple medical viruses, showed an ideal EC<sub>50</sub> value of
12.98 &#x000b1; 5.30 &#x003bc;M against SARS-CoV-2 virus, and its SI was
5.10 &#x000b1; 2.08. For arteannuin B, the EC<sub>50</sub> against
SARS-CoV-2 was 10.28 &#x000b1; 1.12 &#x003bc;M, and a CC<sub>50</sub> of
71.13 &#x000b1; 2.50 &#x003bc;M led to an optimal SI of 7.00 &#x000b1; 0.76
among all artemisinins tested. Interestingly, for lumefantrine,
another antimalarial drug that is structurally distinct from
artemisinins and is a major component of the compound preparation
&#x0201c;coartem&#x0201d;, the EC<sub>50</sub> against SARS-CoV-2 was
23.17 &#x000b1; 3.22 &#x003bc;M, and its SI was greater than 4.40 &#x000b1;
0.61.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Structure and approval status of selected artemisinins.
Green, approved stage; yellow, drugs in preclinical
stage.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_0001" id="gr1" position="float"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Anti-SARS-CoV-2 profile of selected artemisinins. Vero E6
cells were infected with SARS-CoV-2 at an MOI of 0.01 for
treatment with different doses of the indicated antivirals
for 24 h. The viral yield in the cell supernatant was then
quantified by qRT-PCR. The cytotoxicity of these drugs
against Vero E6 cells was measured by performing CCK-8
assays. The red circles and lines indicate the percent
inhibition of the SARS-CoV-2 virus. The green squares
indicate the percent cytotoxicity of the compounds.
Results are representative of <italic>n</italic> = 6 and
are shown as mean &#x000b1; SEM. EC<sub>50</sub> and
CC<sub>50</sub> for each compound were calculated by
4-parameter nonlinear regression model and were plotted by
GraphPad.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_0002" id="gr2" position="float"/></fig></sec><sec id="sec2.2"><title>Artemisinins Reduce the Production of SARS-CoV-2 Protein</title><p>To provide more direct evidence of the inhibitory effect of artemisinins,
an immunofluorescence assay (IFA) was performed. SARS-CoV-2
nucleoprotein (NP) was stained with a specific antibody and detected
with a secondary antibody with a fluorescence label. Inhibition of
fluorescence was observed in a dose-dependent manner for several
artemisinins, as shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>. The expression of viral NP protein was completely
inhibited when arteannuin B was added at 25 &#x003bc;M, and most viral
NP protein was inhibited when artesunate, dihydroartemisinin, and
lumefantrine were added at 25 &#x003bc;M, 25 &#x003bc;M, and 100 &#x003bc;M,
respectively. The IFA results were consistent with the viral yield
based on qRT-PCR analysis (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Immunofluorescence images of virus infection upon treatment
with indicated antivirals. Virus infection and drug
treatment were performed as mentioned previously herein.
The nuclei (blue) were stained with Hoechst dye. The viral
NP protein (green) was stained with rabbit serum against
NP, followed by incubation with the secondary antibody,
specifically Alexa 488-labeled goat anti-rabbit.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_0003" id="gr3" position="float"/></fig></sec><sec id="sec2.3"><title>Arteannuin B and Lumefantrine Block SARS-CoV-2 Infection at the
Post-entry Level</title><p>To explore the antiviral mechanism of the selected drugs, the
time-of-drug-addition assays were performed for arteannuin B and
lumefantrine, which were selected as representatives for different
core structure types (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). Cells were treated with 25 &#x003bc;M arteannuin B or
100 of lumefantrine at different steps of infection (full-time, entry,
and post-entry), which was followed by qRT-PCR, IFA, and Western blot
assays to determine the overall virus replication efficiency. For
arteannuin B, addition of the compounds at the entry step failed to
inhibit the extracellular viral RNA production and intracellular viral
protein expression, but significant inhibition of viral RNA (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A) and viral protein
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B,C) was
observed when the drug was added at the post-entry step. Similarly,
lumefantrine showed inhibitory effects when added during the full-time
infection process or post-entry stage, but not during virus entry
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A,D,E). These
data revealed that arteannuin B and lumefantrine might function at a
similar stage by interfering with the intracellular events of the
SARS-CoV-2 infection cycle, which requires further investigation.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Time-of-drug-addition assay. (A) Viral RNA copies in the
supernatant were quantified by qRT-PCR; (B) NP expression
was visualized after arteannuin B treatment at different
stages. (C) NP expression was quantified by Western blot
assays after arteannuin B treatment at different stages.
(D) NP expression was visualized after lumefantrine
treatment at different stages. (E) NP expression was
quantified by Western blot assays after lumefantrine
treatment at different stages. Results are representative
of <italic>n</italic> = 6 and are mean &#x000b1; SEM;
***<italic>p</italic> &#x0003c; 0.001, significantly
different as indicated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_0004" id="gr4" position="float"/></fig></sec><sec id="sec2.4"><title>Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo
Extrapolation (IVIVE) for Lumefantrine</title><p>The IVIVE could be estimated for most artemisinins due to the known
pharmacokinetic profiles; however, there are limited data on the
pharmacokinetics of lumefantrine. We thus carried out PBPK modeling
and IVIVE for lumefantrine. Due to the low hepatic clearance and
negligible renal excretion of lumefantrine, the prolonged half-life of
up to 6 days in healthy volunteers led to a cumulative effect after
multidose administration.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> As shown in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>, after six oral
doses of 480 mg over 3 days, the EC<sub>50</sub> of lumefantrine was
reached both in plasma and in the lungs. These results suggest the
potential of lumefantrine as a potential anti-SARS-CoV-2 agent.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Predictive performance of the drug distribution of
lumefantrine. (A) Simulated plasma
concentration&#x02013;time profile of lumefantrine
following six oral doses of 480 mg over 3 days. A standard
population size of 100 individuals was used. The solid
line represents the population mean prediction with dashed
lines representing the 5th and 95th percentiles of
prediction. (B) Predicted lung concentration&#x02013;time
profile of lumefantrine following six oral doses of 480 mg
over 3 days. A standard population size of 100 individuals
was used. The solid line represents the population mean
prediction with dashed lines representing the 5th and 95th
percentiles of prediction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_0005" id="gr5" position="float"/></fig></sec></sec><sec id="sec3"><title>Discussion</title><p>During the fight against the COVID-19 pandemic, drug repurposing has been
highlighted, as the known safety and pharmacokinetic profiles of repurposed
drugs indicate that they are more likely to be applied in a timely manner
compared to new drugs. Antimalarial drugs such as chloroquine, quinines, and
artemisinins have long histories of clinical application and have been
reported to have broad-spectrum antiviral potential in recent years.
Chloroquine is effective against influenza virus, dengue virus, and
SARS-CoV-2 <italic>in vitro</italic> and has recently been proven to be
clinically effective against HCV.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Quinines were
reported to have antiviral effects against dengue virus and
HSV-1.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> Artesunate is a structural derivative of artemisinin
characterized by its broad-spectrum antiviral potential against DNA and RNA
viruses.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> In this study, we systematically
evaluated the antiviral potential of artemisinins against SARS-CoV-2
<italic>in vitro</italic> and discovered that artesunate could inhibit
SARS-CoV-2 replication in a dose-dependent manner. Arteannuin B is another
artemisinin derivative that had an ideal EC<sub>50</sub> value, suggesting
its anti-SARS-CoV-2 effect <italic>in vitro</italic>. Interestingly, we
found that the antimalarial drug lumefantrine, which is structurally distant
from artemisinins and is a major component of an approved drug coartem,
could inhibit SARS-CoV-2 <italic>in vitro</italic> with an EC<sub>50</sub>
of 23.17 &#x000b1; 3.22 &#x003bc;M.</p><p>For the emergency use of repurposed drugs, the pharmacokinetic profile is an
important reference for estimating clinical efficacy. The
<italic>C</italic><sub>max</sub> of artesunate was 42 &#x003bc;M
following a single intravenous injection dose of 120 mg, which is greater
than the EC<sub>50</sub> of 13.31 &#x000b1; 1.24 &#x003bc;M (the <italic>in
vivo</italic> metabolite of artesunate was dihydroartemisinin) against
SARS-CoV-2, indicating that artesunate is a potential countermeasure against
COVID-19.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Coartem is a pharmaceutical compound
preparation composed of artemether&#x02013;lumefantrine (20 mg artemether and
120 mg lumefantrine per tablet). The <italic>C</italic><sub>max</sub> of
artemether was found to be low (0.28 &#x003bc;M); however, the
<italic>C</italic><sub>max</sub> of lumefantrine was much higher.
Moreover, the plasma half-life of lumefantrine was determined to be 119 h,
and the long half-life caused drug accumulation, which might lead to
enhanced plasma and tissue drug concentrations.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Indeed,
based on the PBPK model of lumefantrine, the plasma and the lung
concentrations could exceed 23.17 &#x003bc;M (12.26 &#x003bc;g/mL) after six
oral doses of 480 mg over 3 days, which would exceed its EC<sub>50</sub>
value against SARS-CoV-2. Arteannuin B showed anti-SARS-CoV-2 potential with
an EC<sub>50</sub> of 10.28 &#x000b1; 1.12 &#x003bc;M, and its unique core
structure provides information for the future optimization of artemisinins
as anti-SARS-CoV-2 agents.</p><p>Artemisinins, especially artesunate and its active metabolite
dihydroartemisinin, have been shown to have antiviral potential in the
present and previous studies. Accumulating studies have suggested that
artesunate is likely to impair viral infection by modulating host cell
metabolic pathways. In particular, the anti-HCMV efficacy of artesunate is
associated with the PI3-K/Akt/p70S6K signaling pathway. Artesunate was also
found to interact directly or indirectly with cellular DNA-binding factors
such as NF-&#x003ba;B or Sp1, leading to the inhibition of viral
replication.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> For coartem and arteannuin B,
although there are some studies on their antiviral efficacy, our research
has demonstrated their promising therapeutic advantages for the treatment of
SARS-CoV-2 infection <italic>in vitro</italic>. Notably, synergistic effects
of artemisinins and conventional antiviral drugs were observed in antiviral
research, including HCMV, HBV, and bovine viral diarrhea
virus.<sup><xref ref-type="bibr" rid="ref29">29</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref></sup> Facing the global outbreak of SARS-CoV-2, the
combination of artemisinins and other antiviral drugs with different
mechanisms, such as remdesivir and favipiravir, might be a promising
clinical option.</p><p>In summary, we systematically explored the antiviral activities of artemisinins
against SARS-CoV-2 <italic>in vitro</italic>. Artesunate, arteannuin B, and
lumefantrine showed promise as anti-SARS-CoV-2 agents <italic>in
vitro</italic>. Combined with the safety and potential
immunoregulatory activities of artemisinins, we believe that artemisinin
might represent a potential medical countermeasure against COVID-19.</p></sec><sec id="sec4"><title>Methods</title><sec id="sec4.1"><title>Cells and Virus</title><p>Vero E6 cells (ATCC, no. 1586) were grown and maintained in minimum
Eagle&#x02019;s medium (Gibco Invitrogen) supplemented with 10% fetal
bovine serum (Gibco Invitrogen) at 37 &#x000b0;C in 5% CO<sub>2</sub>.
The SARS-CoV-2 strain (nCoV-2019BetaCoV/Wuhan/WIV04/2019) was
propagated, stored, and titrated as previously
described.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> All studies on infectious
viruses were performed in a biosafety level-3 (BLS-3) laboratory.</p></sec><sec id="sec4.2"><title>Cytotoxicity and Antiviral Assays</title><p>Cytotoxicity was evaluated in Vero E6 cells using a cell counting kit-8
(CCK8) (Beyotime, China) according to the manufacturer&#x02019;s
instructions. For the antiviral assay, 4.8 &#x000d7; 10<sup>6</sup> Vero
E6 cells were seeded onto 48-well cell-culture Petri dishes and grown
overnight. After pretreatment with a gradient of diluted experimental
compounds for 1 h at 37 &#x000b0;C, cells were infected with virus at an
MOI of 0.01 for 1 h. After incubation, the inoculum was removed, cells
were washed with PBS, and culture vessels were replenished with fresh
drug-containing medium. At 24 h postinfection, total RNA was extracted
from the supernatant and qRT-PCR was performed to quantify the virus
yield as described previously.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup></p></sec><sec id="sec4.3"><title>Immunofluorescence Assay</title><p>The IFA was performed according to the previous method with
modifications.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Briefly, Vero E6 cells were
inoculated in 48-well cell-culture Petri dishes and grown overnight.
After pretreatment with a gradient of diluted experimental compounds
for 1 h at 37 &#x000b0;C, cells were infected with virus at an MOI of
0.01 for 1 h. After incubation, the inoculum was removed, cells were
washed with PBS, and culture vessels were replenished with fresh
drug-containing medium. At 24 h postinfection, cells were washed with
PBS, fixed with 4% (w/v) paraformaldehyde, and permeabilized with 0.2%
(v/v, in PBS) triton X-100. After blocking with 5% (m/v, in PBS)
bovine serum albumin at 37 &#x000b0;C for 1 h, the cells were further
incubated with the primary antibody, rabbit serum against NP (anti-NP
antibody, 1:1000), followed by incubation with the secondary antibody,
Alexa 488-labeled goat anti-rabbit (1:500; Abcam). The nucleus was
stained with Hoechst 33258 (Beyotime, China). Immunofluorescence
images were obtained using a fluorescence microscope.</p></sec><sec id="sec4.4"><title>Time-of-Drug-Addition Assay</title><p>The time-of-drug-addition assay was performed according to a previous
description.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Briefly, Vero E6 cells were
seeded at 1 &#x000d7; 10<sup>5</sup> cells/well and incubated overnight.
Twenty-five micromolar arteannuin B, 100 &#x003bc;M lumefantrine, or
DMSO was added at the indicated time points. At 16 h postinfection,
the viral NP protein in the infected cells was detected by IFA and
Western blotting. IFA was performed as described previously herein.
Rabbit serum against NP and horseradish peroxidase (HRP)-conjugated
goat anti-rabbit IgG (1:5000; Proteintech, China) were used as primary
and secondary antibodies, respectively, for Western blotting.</p></sec><sec id="sec4.5"><title>Physiologically Based Pharmacokinetic Modeling and Simulations</title><p>PBPK simulations were performed using the Simcyp simulator (version 18,
release 2, Simcyp Limited, Sheffield, U.K.) run on a Lenovo computer
platform with an Intel Core i5 processor. All simulations were carried
out using the virtual clinical trials composed of the prevalidated
built-in &#x0201c;Healthy Volunteer&#x0201d; population groups. The
parameters and methods of PBPK modeling and simulations are available
in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00522/suppl_file/id0c00522_si_001.pdf">Supporting Information</ext-link>.</p></sec><sec id="sec4.6"><title>Data and Statistical Analysis</title><p>The data and statistical analysis in this study complied with the
recommendations on experimental design and analysis in pharmacology.
The data are presented as the mean &#x000b1; SEM. Statistical analyses
between two groups were performed using the unpaired Student&#x02019;s
<italic>t</italic> test. Differences among groups were assessed
by one-way analysis of variance with the Bonferroni post hoc test. In
all cases, a value of <italic>p</italic> &#x0003c; 0.05 was considered
statistically significant.</p></sec><sec id="sec4.7"><title>Materials</title><p>Artemisinin (CAS No. 63968-64-9), artemether (CAS No. 71963-77-4),
artesunate (CAS No. 88495-63-0), dihydroartemisinin (CAS No.
71939-50-9), artemisinic acid (CAS No. 80286-58-4), arteether (CAS No.
75887-54-6), and lumefantrine (CAS No. 82186-77-4) were purchased from
Selleck. Arteannuin B (CAS No. 50906-56-4) and artemisone (CAS No.
255730-18-8) were purchased from MedChemExpress. All compounds were
dissolved in DMSO for subsequent experiments.</p></sec></sec></body><back><notes id="notes-4" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00522?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00522</ext-link>.<list id="silist" list-type="simple"><list-item><p>Detailed methods and
results of PBPK modeling (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00522/suppl_file/id0c00522_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00522_si_001.pdf"><caption><p>id0c00522_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes-1"><title>Author Contributions</title><p><sup>#</sup> R.C., H.H., and Y.L. contributed equally. W.Z., M.W., Z.H., and R.C. conceived
the overall study and designed the experiments. H.H., Y.L., X.W., M.X.,
J.L., H.Z., Y.Y., L.Z., W.L., T.Z., D.X., X.G., Y.L., and J.Y. performed
most of the biological and functional experiments and analyzed the data.
R.C., M.W., and Z.H. wrote and edited the manuscript. All authors have made
important comments regarding the manuscript.</p></notes><notes notes-type="COI-statement" id="notes-3"><p>The authors declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This research was supported by grants from the National Science and Technology
Major Projects (2018ZX09711003) and the National Key Research and
Development Project (2020YFC0841700). We thank Jia Wu, Hao Tang, and Jun Liu
from BSL-3 Laboratory from the Core Faculty of Wuhan Institute of Virology
for their critical support.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="weblink" id="cit1"><person-group><collab>WHO</collab></person-group>.
(<year>2020</year>) <source>Coronavirus disease (COVID-2019)
situation reports - 180</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200718-covid-19-sitrep-180.pdf?sfvrsn=39b31718_2">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200718-covid-19-sitrep-180.pdf?sfvrsn=39b31718_2</uri>
(accessed on July 21, 2020).</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Zhu</surname><given-names>N.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Song</surname><given-names>J.</given-names></name>; <name><surname>Zhao</surname><given-names>X.</given-names></name>; <name><surname>Huang</surname><given-names>B.</given-names></name>; <name><surname>Shi</surname><given-names>W.</given-names></name>; <name><surname>Lu</surname><given-names>R.</given-names></name>; <name><surname>Niu</surname><given-names>P.</given-names></name>; <name><surname>Zhan</surname><given-names>F.</given-names></name>; <name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Wu</surname><given-names>G.</given-names></name>; <name><surname>Gao</surname><given-names>G. F.</given-names></name>; <name><surname>Tan</surname><given-names>W.</given-names></name>; (<year>2020</year>) <article-title>A Novel Coronavirus from Patients with Pneumonia in
China, 2019</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>727</fpage>&#x02013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id>.<pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="weblink" id="cit3"><person-group><collab>National
Institutes of Health</collab></person-group>
(<year>2020</year>) <source>Coronavirus Disease 2019 (2019-nCoV)
Treatment Guidelines</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/">https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/</uri>
(accessed on June 29, 2020).</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Cao</surname><given-names>R.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>M.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Hu</surname><given-names>Z.</given-names></name>; <name><surname>Zhong</surname><given-names>W.</given-names></name>; <name><surname>Xiao</surname><given-names>G.</given-names></name> (<year>2020</year>) <article-title>Remdesivir and chloroquine effectively inhibit the
recently emerged novel coronavirus (2019-nCoV) in
vitro</article-title>. <source>Cell Res.</source>
<volume>30</volume>, <fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Hedya</surname><given-names>S. A.</given-names></name>; <name><surname>Safar</surname><given-names>M. M.</given-names></name>; <name><surname>Bahgat</surname><given-names>A. K.</given-names></name> (<year>2019</year>) <article-title>Hydroxychloroquine antiparkinsonian potential: Nurr1
modulation versus autophagy inhibition</article-title>. <source>Behav. Brain Res.</source>
<volume>365</volume>, <fpage>82</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2019.02.033</pub-id>.<pub-id pub-id-type="pmid">30797853</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Cheong</surname><given-names>D. H. J.</given-names></name>; <name><surname>Tan</surname><given-names>D. W. S.</given-names></name>; <name><surname>Wong</surname><given-names>F. W. S.</given-names></name>; <name><surname>Tran</surname><given-names>T.</given-names></name> (<year>2020</year>) <article-title>Anti-malarial drug, artemisinin and its derivatives for
the treatment of respiratory diseases</article-title>. <source>Pharmacol. Res.</source>
<volume>158</volume>, <fpage>104901</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104901</pub-id>.<pub-id pub-id-type="pmid">32405226</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Uzun</surname><given-names>T.</given-names></name>; <name><surname>Toptas</surname><given-names>O.</given-names></name> (<year>2020</year>) <article-title>Artesunate: could be an alternative drug to chloroquine
in COVID-19 treatment?</article-title>. <source>Chin. Med.</source>
<volume>15</volume>, <fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13020-020-00336-8</pub-id>.<pub-id pub-id-type="pmid">32514287</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Ho</surname><given-names>W. E.</given-names></name>; <name><surname>Peh</surname><given-names>H. Y.</given-names></name>; <name><surname>Chan</surname><given-names>T. K.</given-names></name>; <name><surname>Wong</surname><given-names>W. S.</given-names></name> (<year>2014</year>) <article-title>Artemisinins: pharmacological actions beyond
anti-malarial</article-title>. <source>Pharmacol. Ther.</source>
<volume>142</volume>, <fpage>126</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.001</pub-id>.<pub-id pub-id-type="pmid">24316259</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Afolabi</surname><given-names>B. B.</given-names></name>; <name><surname>Okoromah</surname><given-names>C. N.</given-names></name> (<year>2004</year>) <article-title>Intramuscular arteether for treating severe
malaria</article-title>. <source>Cochrane Database Syst. Rev.</source>
<volume>2004</volume>, <fpage>CD004391</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004391.pub2</pub-id>.</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Sinclair</surname><given-names>D.</given-names></name>; <name><surname>Zani</surname><given-names>B.</given-names></name>; <name><surname>Donegan</surname><given-names>S.</given-names></name>; <name><surname>Olliaro</surname><given-names>P.</given-names></name>; <name><surname>Garner</surname><given-names>P.</given-names></name> (<year>2009</year>) <article-title>Artemisinin-based combination therapy for treating
uncomplicated malaria</article-title>. <source>Cochrane Database Syst. Rev.</source>
<volume>2009</volume>, <fpage>CD007483</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD007483.pub2</pub-id>.</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Waknine-Grinberg</surname><given-names>J. H.</given-names></name>; <name><surname>Hunt</surname><given-names>N.</given-names></name>; <name><surname>Bentura-Marciano</surname><given-names>A.</given-names></name>; <name><surname>McQuillan</surname><given-names>J. A.</given-names></name>; <name><surname>Chan</surname><given-names>H. W.</given-names></name>; <name><surname>Chan</surname><given-names>W. C.</given-names></name>; <name><surname>Barenholz</surname><given-names>Y.</given-names></name>; <name><surname>Haynes</surname><given-names>R. K.</given-names></name>; <name><surname>Golenser</surname><given-names>J.</given-names></name> (<year>2010</year>) <article-title>Artemisone effective against murine cerebral
malaria</article-title>. <source>Malar. J.</source>
<volume>9</volume>, <fpage>227</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-9-227</pub-id>.<pub-id pub-id-type="pmid">20691118</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Cai</surname><given-names>T. Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Y. R.</given-names></name>; <name><surname>Ji</surname><given-names>J. B.</given-names></name>; <name><surname>Xing</surname><given-names>J.</given-names></name> (<year>2017</year>) <article-title>Investigation of the component in Artemisia annua L.
leading to enhanced antiplasmodial potency of artemisinin via
regulation of its metabolism</article-title>. <source>J. Ethnopharmacol.</source>
<volume>207</volume>, <fpage>86</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2017.06.025</pub-id>.<pub-id pub-id-type="pmid">28642094</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>M. H.</given-names></name>; <name><surname>Lee</surname><given-names>J. H.</given-names></name>; <name><surname>Jung</surname><given-names>E.</given-names></name>; <name><surname>Yoo</surname><given-names>E. S.</given-names></name>; <name><surname>Park</surname><given-names>D.</given-names></name> (<year>2012</year>) <article-title>Artemisinic acid is a regulator of adipocyte
differentiation and /EBP delta expression</article-title>. <source>J. Cell. Biochem.</source>
<volume>113</volume>, <fpage>2488</fpage>&#x02013;<lpage>2499</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.24124</pub-id>.<pub-id pub-id-type="pmid">22396222</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Romero</surname><given-names>M. R.</given-names></name>; <name><surname>Wolf</surname><given-names>D. G.</given-names></name>; <name><surname>Stamminger</surname><given-names>T.</given-names></name>; <name><surname>Marin</surname><given-names>J. J.</given-names></name>; <name><surname>Marschall</surname><given-names>M.</given-names></name> (<year>2008</year>) <article-title>The antiviral activities of artemisinin and
artesunate</article-title>. <source>Clin. Infect. Dis.</source>
<volume>47</volume>, <fpage>804</fpage>&#x02013;<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1086/591195</pub-id>.<pub-id pub-id-type="pmid">18699744</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Raffetin</surname><given-names>A.</given-names></name>; <name><surname>Bruneel</surname><given-names>F.</given-names></name>; <name><surname>Roussel</surname><given-names>C.</given-names></name>; <name><surname>Thellier</surname><given-names>M.</given-names></name>; <name><surname>Buffet</surname><given-names>P.</given-names></name>; <name><surname>Caumes</surname><given-names>E.</given-names></name>; <name><surname>Jaureguiberry</surname><given-names>S.</given-names></name> (<year>2018</year>) <article-title>Use of artesunate in non-malarial
indications</article-title>. <source>Med. Mal. Infect.</source>
<volume>48</volume>, <fpage>238</fpage>&#x02013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1016/j.medmal.2018.01.004</pub-id>.<pub-id pub-id-type="pmid">29422423</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Shapira</surname><given-names>M. Y.</given-names></name>; <name><surname>Resnick</surname><given-names>I. B.</given-names></name>; <name><surname>Chou</surname><given-names>S.</given-names></name>; <name><surname>Neumann</surname><given-names>A. U.</given-names></name>; <name><surname>Lurain</surname><given-names>N. S.</given-names></name>; <name><surname>Stamminger</surname><given-names>T.</given-names></name>; <name><surname>Caplan</surname><given-names>O.</given-names></name>; <name><surname>Saleh</surname><given-names>N.</given-names></name>; <name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Marschall</surname><given-names>M.</given-names></name>; <name><surname>Wolf</surname><given-names>D. G.</given-names></name> (<year>2008</year>) <article-title>Artesunate as a potent antiviral agent in a patient
with late drug-resistant cytomegalovirus infection after
hematopoietic stem cell transplantation</article-title>. <source>Clin. Infect. Dis.</source>
<volume>46</volume>, <fpage>1455</fpage>&#x02013;<lpage>1457</lpage>. <pub-id pub-id-type="doi">10.1086/587106</pub-id>.<pub-id pub-id-type="pmid">18419454</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Flobinus</surname><given-names>A.</given-names></name>; <name><surname>Taudon</surname><given-names>N.</given-names></name>; <name><surname>Desbordes</surname><given-names>M.</given-names></name>; <name><surname>Labrosse</surname><given-names>B.</given-names></name>; <name><surname>Simon</surname><given-names>F.</given-names></name>; <name><surname>Mazeron</surname><given-names>M. C.</given-names></name>; <name><surname>Schnepf</surname><given-names>N.</given-names></name> (<year>2014</year>) <article-title>Stability and antiviral activity against human
cytomegalovirus of artemisinin derivatives</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>69</volume>, <fpage>34</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkt346</pub-id>.<pub-id pub-id-type="pmid">24003183</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Han</surname><given-names>Y.</given-names></name>; <name><surname>Pham</surname><given-names>H. T.</given-names></name>; <name><surname>Xu</surname><given-names>H.</given-names></name>; <name><surname>Quan</surname><given-names>Y.</given-names></name>; <name><surname>Mesplede</surname><given-names>T.</given-names></name> (<year>2019</year>) <article-title>Antimalarial drugs and their metabolites are potent
Zika virus inhibitors</article-title>. <source>J. Med. Virol.</source>
<volume>91</volume>, <fpage>1182</fpage>&#x02013;<lpage>1190</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25440</pub-id>.<pub-id pub-id-type="pmid">30801742</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Oiknine-Djian</surname><given-names>E.</given-names></name>; <name><surname>Bar-On</surname><given-names>S.</given-names></name>; <name><surname>Laskov</surname><given-names>I.</given-names></name>; <name><surname>Lantsberg</surname><given-names>D.</given-names></name>; <name><surname>Haynes</surname><given-names>R. K.</given-names></name>; <name><surname>Panet</surname><given-names>A.</given-names></name>; <name><surname>Wolf</surname><given-names>D. G.</given-names></name> (<year>2019</year>) <article-title>Artemisone demonstrates synergistic antiviral activity
in combination with approved and experimental drugs active
against human cytomegalovirus</article-title>. <source>Antiviral Res.</source>
<volume>172</volume>, <fpage>104639</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104639</pub-id>.<pub-id pub-id-type="pmid">31654672</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Oiknine-Djian</surname><given-names>E.</given-names></name>; <name><surname>Weisblum</surname><given-names>Y.</given-names></name>; <name><surname>Panet</surname><given-names>A.</given-names></name>; <name><surname>Wong</surname><given-names>H. N.</given-names></name>; <name><surname>Haynes</surname><given-names>R. K.</given-names></name>; <name><surname>Wolf</surname><given-names>D. G.</given-names></name> (<year>2018</year>) <article-title>The Artemisinin Derivative Artemisone Is a Potent
Inhibitor of Human Cytomegalovirus Replication</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>62</volume>, <fpage>e00288</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00288-18</pub-id>.<pub-id pub-id-type="pmid">29712656</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Borrmann</surname><given-names>S.</given-names></name>; <name><surname>Sallas</surname><given-names>W. M.</given-names></name>; <name><surname>Machevo</surname><given-names>S.</given-names></name>; <name><surname>Gonz&#x000e1;lez</surname><given-names>R.</given-names></name>; <name><surname>Bj&#x000f6;rkman</surname><given-names>A.</given-names></name>; <name><surname>M&#x000e5;rtensson</surname><given-names>A.</given-names></name>; <name><surname>Hamel</surname><given-names>M.</given-names></name>; <name><surname>Juma</surname><given-names>E.</given-names></name>; <name><surname>Peshu</surname><given-names>J.</given-names></name>; <name><surname>Ogutu</surname><given-names>B.</given-names></name>; <name><surname>Djimd&#x000e9;</surname><given-names>A.</given-names></name>; <name><surname>D&#x02019;Alessandro</surname><given-names>U.</given-names></name>; <name><surname>Marrast</surname><given-names>A. C.</given-names></name>; <name><surname>Lef&#x000e8;vre</surname><given-names>G.</given-names></name>; <name><surname>Kern</surname><given-names>S. E.</given-names></name> (<year>2010</year>) <article-title>The effect of food consumption on lumefantrine
bioavailability in African children receiving
artemether-lumefantrine crushed or dispersible tablets (Coartem)
for acute uncomplicated Plasmodium falciparum
malaria</article-title>. <source>Trop. Med. Int. Health</source>
<volume>15</volume>, <fpage>434</fpage>&#x02013;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3156.2010.02477.x</pub-id>.<pub-id pub-id-type="pmid">20180933</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Peymani</surname><given-names>P.</given-names></name>; <name><surname>Yeganeh</surname><given-names>B.</given-names></name>; <name><surname>Sabour</surname><given-names>S.</given-names></name>; <name><surname>Geramizadeh</surname><given-names>B.</given-names></name>; <name><surname>Fattahi</surname><given-names>M. R.</given-names></name>; <name><surname>Keyvani</surname><given-names>H.</given-names></name>; <name><surname>Azarpira</surname><given-names>N.</given-names></name>; <name><surname>Coombs</surname><given-names>K. M.</given-names></name>; <name><surname>Ghavami</surname><given-names>S.</given-names></name>; <name><surname>Lankarani</surname><given-names>K. B.</given-names></name> (<year>2016</year>) <article-title>New use of an old drug: chloroquine reduces viral and
ALT levels in HCV non-responders (a randomized, triple-blind,
placebo-controlled pilot trial)</article-title>. <source>Can. J. Physiol. Pharmacol.</source>
<volume>94</volume>, <fpage>613</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1139/cjpp-2015-0507</pub-id>.<pub-id pub-id-type="pmid">26998724</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Baroni</surname><given-names>A.</given-names></name>; <name><surname>Paoletti</surname><given-names>I.</given-names></name>; <name><surname>Ruocco</surname><given-names>E.</given-names></name>; <name><surname>Ayala</surname><given-names>F.</given-names></name>; <name><surname>Corrado</surname><given-names>F.</given-names></name>; <name><surname>Wolf</surname><given-names>R.</given-names></name>; <name><surname>Tufano</surname><given-names>M. A.</given-names></name>; <name><surname>Donnarumma</surname><given-names>G.</given-names></name> (<year>2007</year>) <article-title>Antiviral effects of quinine sulfate on HSV-1 HaCat
cells infected: analysis of the molecular mechanisms
involved</article-title>. <source>J. Dermatol. Sci.</source>
<volume>47</volume>, <fpage>253</fpage>&#x02013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdermsci.2007.05.009</pub-id>.<pub-id pub-id-type="pmid">17600687</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Malakar</surname><given-names>S.</given-names></name>; <name><surname>Sreelatha</surname><given-names>L.</given-names></name>; <name><surname>Dechtawewat</surname><given-names>T.</given-names></name>; <name><surname>Noisakran</surname><given-names>S.</given-names></name>; <name><surname>Yenchitsomanus</surname><given-names>P. T.</given-names></name>; <name><surname>Chu</surname><given-names>J. J. H.</given-names></name>; <name><surname>Limjindaporn</surname><given-names>T.</given-names></name> (<year>2018</year>) <article-title>Drug repurposing of quinine as antiviral against dengue
virus infection</article-title>. <source>Virus Res.</source>
<volume>255</volume>, <fpage>171</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2018.07.018</pub-id>.<pub-id pub-id-type="pmid">30055216</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Ilett</surname><given-names>K. F.</given-names></name>; <name><surname>Batty</surname><given-names>K. T.</given-names></name>; <name><surname>Powell</surname><given-names>S. M.</given-names></name>; <name><surname>Binh</surname><given-names>T. Q.</given-names></name>; <name><surname>Thu</surname><given-names>l.</given-names></name>; <name><surname>Phuong</surname><given-names>H. L.</given-names></name>; <name><surname>Hung</surname><given-names>N. C.</given-names></name>; <name><surname>Davis</surname><given-names>T. M.</given-names></name> (<year>2002</year>) <article-title>The pharmacokinetic properties of intramuscular
artesunate and rectal dihydroartemisinin in uncomplicated
falciparum malaria</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<volume>53</volume>, <fpage>23</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1046/j.0306-5251.2001.01519.x</pub-id>.<pub-id pub-id-type="pmid">11849191</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="undeclared" id="cit26"><person-group><collab>FDA</collab></person-group>
(<year>2020</year>) <source>COARTEM&#x000ae; (artemether and
lumefantrine) tablets for oral use</source>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022268s021lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022268s021lbl.pdf</uri>
(accessed on June 18th, 2020).</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Eickhoff</surname><given-names>J.</given-names></name>; <name><surname>Hanke</surname><given-names>M.</given-names></name>; <name><surname>Stein-Gerlach</surname><given-names>M.</given-names></name>; <name><surname>Kiang</surname><given-names>T. P.</given-names></name>; <name><surname>Herzberger</surname><given-names>K.</given-names></name>; <name><surname>Habenberger</surname><given-names>P.</given-names></name>; <name><surname>M&#x000fc;ller</surname><given-names>S.</given-names></name>; <name><surname>Klebl</surname><given-names>B.</given-names></name>; <name><surname>Marschall</surname><given-names>M.</given-names></name>; <name><surname>Stamminger</surname><given-names>T.</given-names></name>; <name><surname>Cotten</surname><given-names>M.</given-names></name> (<year>2004</year>) <article-title>RICK activates a NF-kappaB-dependent anti-human
cytomegalovirus response</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>9642</fpage>&#x02013;<lpage>9652</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M312893200</pub-id>.<pub-id pub-id-type="pmid">14670961</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Marschall</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Huong</surname><given-names>S. M.</given-names></name>; <name><surname>Hauber</surname><given-names>I.</given-names></name>; <name><surname>Olbrich</surname><given-names>A.</given-names></name>; <name><surname>Kronschnabl</surname><given-names>M.</given-names></name>; <name><surname>Stamminger</surname><given-names>T.</given-names></name>; <name><surname>Huang</surname><given-names>E. S.</given-names></name> (<year>2002</year>) <article-title>Antiviral activity of artesunate towards wild-type,
recombinant, and ganciclovir-resistant human
cytomegaloviruses</article-title>. <source>J. Mol. Med. (Heidelberg, Ger.)</source>
<volume>80</volume>, <fpage>233</fpage>&#x02013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-001-0300-8</pub-id>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Kaptein</surname><given-names>S. J.</given-names></name>; <name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Leis</surname><given-names>M.</given-names></name>; <name><surname>Rechter</surname><given-names>S.</given-names></name>; <name><surname>Auerochs</surname><given-names>S.</given-names></name>; <name><surname>Kalmer</surname><given-names>M.</given-names></name>; <name><surname>Bruggeman</surname><given-names>C. A.</given-names></name>; <name><surname>Vink</surname><given-names>C.</given-names></name>; <name><surname>Stamminger</surname><given-names>T.</given-names></name>; <name><surname>Marschall</surname><given-names>M.</given-names></name> (<year>2006</year>) <article-title>The anti-malaria drug artesunate inhibits replication
of cytomegalovirus in vitro and in vivo</article-title>. <source>Antiviral Res.</source>
<volume>69</volume>, <fpage>60</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.10.003</pub-id>.<pub-id pub-id-type="pmid">16325931</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Romero</surname><given-names>M. R.</given-names></name>; <name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Serrano</surname><given-names>M. A.</given-names></name>; <name><surname>Casta&#x000f1;o</surname><given-names>B.</given-names></name>; <name><surname>Macias</surname><given-names>R. I. R.</given-names></name>; <name><surname>Briz</surname><given-names>O.</given-names></name>; <name><surname>Marin</surname><given-names>J. J. G.</given-names></name> (<year>2005</year>) <article-title>Effect of artemisinin/artesunate as inhibitors of
hepatitis B virus production in an &#x0201c;in vitro&#x0201d;
replicative system</article-title>. <source>Antiviral Res.</source>
<volume>68</volume>, <fpage>75</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.07.005</pub-id>.<pub-id pub-id-type="pmid">16122816</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Romero</surname><given-names>M. R.</given-names></name>; <name><surname>Serrano</surname><given-names>M. A.</given-names></name>; <name><surname>Vallejo</surname><given-names>M.</given-names></name>; <name><surname>Efferth</surname><given-names>T.</given-names></name>; <name><surname>Alvarez</surname><given-names>M.</given-names></name>; <name><surname>Marin</surname><given-names>J. J.</given-names></name> (<year>2006</year>) <article-title>Antiviral effect of artemisinin from Artemisia annua
against a model member of the Flaviviridae family, the bovine
viral diarrhoea virus (BVDV)</article-title>. <source>Planta Med.</source>
<volume>72</volume>, <fpage>1169</fpage>&#x02013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1055/s-2006-947198</pub-id>.<pub-id pub-id-type="pmid">16902856</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Ren</surname><given-names>L.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Fan</surname><given-names>G.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>W.</given-names></name>; <name><surname>Xie</surname><given-names>X.</given-names></name>; <name><surname>Yin</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Xiao</surname><given-names>Y.</given-names></name>; <name><surname>Gao</surname><given-names>H.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Xie</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>; <name><surname>Jiang</surname><given-names>R.</given-names></name>; <name><surname>Gao</surname><given-names>Z.</given-names></name>; <name><surname>Jin</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Cao</surname><given-names>B.</given-names></name> (<year>2020</year>) <article-title>Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>497</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Zhou</surname><given-names>P.</given-names></name>; <name><surname>Yang</surname><given-names>X. L.</given-names></name>; <name><surname>Wang</surname><given-names>X. G.</given-names></name>; <name><surname>Hu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Si</surname><given-names>H. R.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>B.</given-names></name>; <name><surname>Huang</surname><given-names>C. L.</given-names></name>; <name><surname>Chen</surname><given-names>H. D.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Luo</surname><given-names>Y.</given-names></name>; <name><surname>Guo</surname><given-names>H.</given-names></name>; <name><surname>Jiang</surname><given-names>R. D.</given-names></name>; <name><surname>Liu</surname><given-names>M. Q.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Shen</surname><given-names>X. R.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zheng</surname><given-names>X. S.</given-names></name>; <name><surname>Zhao</surname><given-names>K.</given-names></name>; <name><surname>Chen</surname><given-names>Q. J.</given-names></name>; <name><surname>Deng</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>L. L.</given-names></name>; <name><surname>Yan</surname><given-names>B.</given-names></name>; <name><surname>Zhan</surname><given-names>F. X.</given-names></name>; <name><surname>Wang</surname><given-names>Y. Y.</given-names></name>; <name><surname>Xiao</surname><given-names>G. F.</given-names></name>; <name><surname>Shi</surname><given-names>Z. L.</given-names></name> (<year>2020</year>) <article-title>A pneumonia outbreak associated with a new coronavirus
of probable bat origin</article-title>. <source>Nature</source>
<volume>579</volume>, <fpage>270</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>.<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref></ref-list></back></article>